Pfizer's Oral Weight Loss Drug Shows Promise in Clinical Trials.
TL;DR Summary
Pfizer's GLP-1 agonist has shown potential for weight loss in people with type 2 diabetes, according to new Phase II data published in the JAMA network. The drug is part of a growing field of obesity drugs, many of which started as diabetes medications, and are expected to become the biggest drug class in history with more than $100 billion on the line.
- Pfizer’s oral GLP-1 shows weight loss potential in new PhII data Endpoints News
- Efficacy of Pfizer's weight-loss drug 'inferior' to others on the market, says UBS's Colin Bristow CNBC Television
- Pfizer oral weight loss drug may be as effective as Ozempic injection by Novo Nordisk, study says CNBC
- Pfizer stock rises on positive results from weight loss drug study Yahoo Finance
- In obesity trial, Novo Nordisk hits the mark with oral Wegovy FiercePharma
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
7 min
vs 7 min read
Condensed
95%
1,377 → 63 words
Want the full story? Read the original article
Read on Endpoints News